An Open-Label Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Tivozanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AVEO Oncology
- 23 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 23 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jun 2011 Planned End Date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.